• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Arrowhead Pharmaceuticals Announces Global License and Collaboration Agreement with Sarepta Therapeutics for Multiple Clinical and Preclinical Programs

    11/26/24 7:00:00 AM ET
    $ARWR
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARWR alert in real time by email

    - Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five years

    - Arrowhead has potential to receive an additional $300 million in near-term clinical trial enrollment-related milestone payments and is eligible for future potential milestone payments up to $10 billion and royalties on sales

    - Sarepta to receive investigational treatments that leverage Arrowhead's leading Targeted RNAi Molecule platform

    - Arrowhead to discuss this agreement during the company's 2024 fiscal year end results conference call today, November 26, 2024, at 4:30 p.m. ET

    Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced a global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ:SRPT). Upon closing, Arrowhead will receive $825 million, consisting of $500 million cash and $325 million as an equity investment priced at a 35% premium. Arrowhead also receives $250 million to be paid in equal installments over five years and is eligible to receive an additional $300 million in near-term payments, which Arrowhead is on track to achieve during the next 12 months. Additionally, Arrowhead is eligible to receive royalties on commercial sales and up to approximately $10 billion in future potential milestone payments.

    The agreement covers multiple clinical and preclinical programs in rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs, as well as allows Sarepta to select up to six new targets for Arrowhead to conduct discovery and preclinical development activities in areas complementary to Sarepta's leadership in precision genetic medicine for rare diseases, which can utilize Arrowhead's proprietary and differentiated Targeted RNAi Molecule (TRiM™) platform.

    "For Arrowhead, this strategic transaction accomplishes several important goals that we see as critical to our success as we move from a development stage company operating in several therapeutic areas to a more focused commercial stage company over the coming years. It provides us with a transformational amount of capital immediately and the potential for significant non-dilutive cash throughout the duration of the collaboration. We estimate that this transaction extends Arrowhead's cash runway into 2028 and potentially through multiple new drug launches, including wholly owned and partnered programs. We now turn our focus as a company to launching investigational plozasiran for the treatment of familial chylomicronemia syndrome potentially in 2025, pending FDA review and approval, which would be our first commercial product. We are also prioritizing further development of additional pipeline programs which would be complementary to plozasiran from a clinical, regulatory, and commercial perspective," said Christopher Anzalone, Ph.D., president and CEO at Arrowhead. "With this agreement we also welcome the Sarepta team as new Arrowhead collaboration partners who bring a wealth of clinical, regulatory, and commercial expertise in key areas outside of our cardiometabolic focus. We have a very efficient drug discovery engine that continues to generate many promising programs and we have great confidence in Sarepta's ability to take the next steps to advance and commercialize multiple Arrowhead-discovered drug candidates, which we believe have the potential to be best-in-class."

    At the close of the agreement, Doug Ingram, president and CEO of Sarepta, will be appointed to the Arrowhead Board of Directors. He is an experienced biotech and pharma executive and has led Sarepta as they advanced multiple investigational medicines through the clinical and regulatory process, built a commercial organization from the ground up, launched multiple drugs, and moved the company toward profitability. His experience and guidance will be valuable to Arrowhead as the Company seeks the same transition.

    Mr. Ingram added, "The agreement marks the start of a synergistic relationship with Arrowhead's leading siRNA technology and Sarepta's proven success in bringing rare disease treatments to patients. Together, we will expedite the development of Arrowhead's promising scientific approach and bring best-in-class treatments to patients with devastating rare diseases where treatment options are limited or do not exist. I am honored to serve on the Arrowhead Board of Directors and to help Arrowhead advance its extraordinary science for the benefit of patients around the world."

    Summary Financial Terms

    Upon closing, Arrowhead will receive a $500 million upfront payment and $325 million through the purchase by Sarepta of Arrowhead common stock priced at a 35% premium to the 30-day volume weighted average price. Arrowhead will also receive $250 million to be paid in annual installments of $50 million over 5 years. Arrowhead also has the potential to receive $300 million in near-term payments associated with the continued enrollment of certain cohorts of a Phase 1/2 study, which Arrowhead is on track to achieve during the next 12 months.

    Arrowhead is eligible to receive development milestone payments of between $110 million and $410 million per program and sales milestone payments of between $500 million and $700 million per program. Arrowhead is also eligible to receive tiered royalties on commercial sales up to the low double digits.

    Summary of Programs under License and Collaboration Agreement

    Clinical Stage

    • ARO-DUX4, which is designed to target the gene that encodes the DUX4 protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy type 1, currently dosing patients in a Phase 1/2 clinical study.
    • ARO-DM1, which is designed to reduce expression of the dystrophia myotonica protein kinase, or DMPK, gene in skeletal muscle as a potential treatment for patients with type 1 myotonic dystrophy, currently dosing patients in a Phase 1/2 clinical study.
    • ARO-MMP7, which is designed to reduce expression of matrix metalloproteinase 7, or MMP7, in the lung as a potential treatment for idiopathic pulmonary fibrosis, currently dosing patients in a Phase 1/2 clinical study.
    • ARO-ATXN2, which is designed to silence expression of the toxic ATXN2 protein in the CNS as a potential treatment for spinocerebellar ataxia 2 (SCA2), currently in a Phase 1/2 study that is open for enrollment.

    Preclinical Stage

    • ARO-HTT for patients Huntington's disease expected to be CTA-ready in 2025
    • ARO-ATXN1 for patients with spinocerebellar ataxia 1 (SCA1) expected to be CTA-ready in 2026
    • ARO-ATXN3 for patients with spinocerebellar ataxia 3 (SCA3) expected to be CTA-ready in 2026

    Discovery

    • During the five-year term, Sarepta can propose up to six new CNS or muscle targets for which Arrowhead will perform discovery and preclinical development. Sarepta would then receive an exclusive license to those programs and be responsible for clinical development and commercialization.

    Drug Manufacturing

    Under the agreement, Arrowhead will manufacture clinical drug supply for all programs arising out of the license and collaboration, and commercial drug product for the four programs currently in clinical trials.

    The transaction is expected to close in early 2025, subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.

    Gibson, Dunn & Crutcher LLP is serving as legal advisor to Arrowhead.

    Webcast and Conference Call and Details

    Arrowhead will discuss this agreement during its 2024 fiscal year-end results conference call today, November 26, 2024, at 4:30 p.m. ET.

    Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.

    For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BIc060a13ae8224934aac09d48abe7b2f6. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.

    About Arrowhead Pharmaceuticals

    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

    For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

    Safe Harbor Statement under the Private Securities Litigation Reform Act:

    This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

    Source: Arrowhead Pharmaceuticals, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241126762896/en/

    Get the next $ARWR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Q&A

    New
    • What is the total immediate payment Arrowhead Pharmaceuticals will receive from the collaboration with Sarepta?

      Arrowhead Pharmaceuticals will receive an immediate payment of $825 million, which includes an upfront payment of $500 million and an equity investment of $325 million at a 35% premium. Additionally, Arrowhead will receive $250 million over five years in equal installments.

    • What additional financial benefits could Arrowhead Pharmaceuticals receive from the collaboration beyond the immediate payment?

      Arrowhead has the potential to receive up to approximately $10 billion in future milestone payments along with royalties on commercial sales of products developed through the collaboration with Sarepta.

    • What opportunities does the agreement provide in terms of new targets for Arrowhead's technology?

      The agreement allows Sarepta to select up to six new targets for Arrowhead to conduct discovery and preclinical development activities, expanding their collaboration in the development of treatments for rare diseases.

    • When will Arrowhead Pharmaceuticals discuss the new collaboration agreement with Sarepta?

      Arrowhead plans to discuss this licensing agreement during its 2024 fiscal year-end results conference call scheduled for November 26, 2024, at 4:30 p.m. ET.

    • Who from Sarepta will join the Arrowhead Board of Directors and what is his background?

      Doug Ingram, president and CEO of Sarepta, will be appointed to the Arrowhead Board of Directors following the agreement, bringing his extensive experience in the biotech industry to the company.

    Recent Analyst Ratings for
    $ARWR
    $SRPT

    CompanyDatePrice TargetRatingAnalyst
    Sarepta Therapeutics Inc.
    $SRPT
    6/20/2025Outperform → Mkt Perform
    William Blair
    Sarepta Therapeutics Inc.
    $SRPT
    6/18/2025$24.00Buy → Hold
    TD Cowen
    Sarepta Therapeutics Inc.
    $SRPT
    6/17/2025Peer Perform
    Wolfe Research
    Sarepta Therapeutics Inc.
    $SRPT
    6/16/2025Overweight → Equal-Weight
    Morgan Stanley
    Sarepta Therapeutics Inc.
    $SRPT
    6/16/2025Overweight → Neutral
    Cantor Fitzgerald
    Sarepta Therapeutics Inc.
    $SRPT
    6/16/2025Buy → Neutral
    BofA Securities
    Sarepta Therapeutics Inc.
    $SRPT
    6/16/2025$70.00Outperform → Market Perform
    BMO Capital Markets
    Sarepta Therapeutics Inc.
    $SRPT
    6/16/2025$36.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $ARWR
    $SRPT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      8/20/24 8:00:04 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lu Hongbo bought $82,990 worth of shares (3,000 units at $27.66), increasing direct ownership by 10% to 33,680 units (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      3/20/24 7:06:58 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barry Richard bought $3,940,500 worth of shares (50,000 units at $78.81) (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      11/6/23 8:00:11 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    $SRPT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

      - Zodasiran targets ANGPLT3, an emerging therapeutic target to treat HoFH and other dyslipidemias - YOSEMITE Phase 3 study further enhances Arrowhead's late-stage pipeline of RNAi-based cardiometabolic candidates Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia (HoFH), a rare genetic condition that leads to severely elevated LDL-cholesterol and early onset cardiovascular disease. Zodasiran is the fourth investigational RNAi-based candida

      7/8/25 7:30:00 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2025 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta's 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 53 individuals hired by Sarepta in the second quarter of 2025. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 22,016 shares of Sarepta's common stock, and in the aggregate 317,317 restricted stock units ("RSUs"). The options have an exercise price of $17.10 per share,

      6/30/25 6:26:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran

      - Study completion anticipated in mid-2026 with subsequent data readout and regulatory submissions for treatment of severe hypertriglyceridemia Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned submissions for regulatory review and potential approval to follow. The company previously s

      6/23/25 7:30:00 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    $SRPT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

      Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

      7/12/24 4:40:36 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

      For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

      6/20/24 5:24:42 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

      Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

      6/5/24 4:41:31 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    $SRPT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sarepta Therapeutics downgraded by William Blair

      William Blair downgraded Sarepta Therapeutics from Outperform to Mkt Perform

      6/20/25 7:52:50 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics downgraded by TD Cowen with a new price target

      TD Cowen downgraded Sarepta Therapeutics from Buy to Hold and set a new price target of $24.00

      6/18/25 7:45:18 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Sarepta Therapeutics

      Wolfe Research initiated coverage of Sarepta Therapeutics with a rating of Peer Perform

      6/17/25 7:51:08 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    $SRPT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Barry Richard exercised 12,350 shares at a strike of $32.63, increasing direct ownership by 0.42% to 2,966,667 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      5/19/25 7:32:14 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Barry Richard exercised 20,246 shares at a strike of $19.23, increasing direct ownership by 0.69% to 2,954,317 units (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      5/15/25 7:00:11 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Anzalone Christopher Richard sold $1,533,337 worth of shares (141,122 units at $10.87), decreasing direct ownership by 3% to 3,921,255 units (SEC Form 4)

      4 - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Issuer)

      4/11/25 6:20:07 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    $SRPT
    SEC Filings

    See more
    • Sarepta Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      6/6/25 4:30:31 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Arrowhead Pharmaceuticals Inc.

      SCHEDULE 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      5/13/25 10:26:33 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Filer)

      5/12/25 4:10:03 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    $SRPT
    Leadership Updates

    Live Leadership Updates

    See more
    • Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

      Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company's new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition. "Ken has been a valuable member of the Arrowhead team, and he retires at a time of great financial strength for the company. The finance organization that Ken built over the years is very capable and provides strong support to our ambitious development and commercialization plans.

      4/15/25 4:00:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

      NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi

      1/22/25 5:54:00 PM ET
      $APO
      $ARWR
      $B
      $GWRE
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

      - Veteran biopharmaceutical executive from GSK and Eli Lilly brings more than 30 years of experience to Sarepta's Board Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a well-regarded executive with more than 30 years of experience in the pharmaceutical industry. Following Connelly's appointment, Sarepta's Board will comprise nine directors, eight of whom are independent. "Ms. Connelly is a seasoned board leader with extensive operating experience in biopharma and we're pleased to welcome her to the Sarepta Board of Directors as we work to

      9/16/24 8:30:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    $SRPT
    Financials

    Live finance-specific insights

    See more
    • Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

      - The Company is developing an enhanced immunosuppressive regimen in consultation with a panel of multi-disciplinary clinical experts and engaging with regulators - Shipments of ELEVIDYS for infusions in non-ambulatory patients in commercial setting are suspended until enhanced regimen is approved and in place - ENVISION study is paused while seeking a protocol amendment to incorporate additional immunosuppression - Sarepta to host investor call on June 16, 2025, at 8:00 am Eastern time Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding ELEVIDYS (delandistrogene moxeparvovec-rokl), the only a

      6/15/25 1:00:00 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

      - Conference Call and Webcast Today, May 12, 2025, at 4:30 p.m. ET Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, at 4:30 p.m. ET to discuss the results. "Arrowhead is in a strong and stable position as a business, and we have made meaningful progress towards our long-term goal of developing and ultimately commercializing new innovative medicines for millions of patients. We are on schedule to launch plozasiran this year, pending regulatory approval, with what we think is a best-in-class profile with meaningful differentiation from current

      5/12/25 4:01:00 PM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments

      Net product revenues for the first quarter 2025 totaled $611.5 million, a 70% increase over the same quarter of the prior year ELEVIDYS net product revenue for the first quarter totaled $375.0 million; Royalty revenue from the sales of ELEVIDYS by Roche for the quarter totaled $4.0 million Revised 2025 total net product revenues guidance to $2.3 to $2.6 billion Meaningfully advanced multiple clinical candidates in limb-girdle muscular dystrophy portfolio Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the first quarter 2025. "In the first quarter, we achieved net product revenue of $611.5 mi

      5/6/25 4:05:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARWR
    $SRPT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Arrowhead Pharmaceuticals Inc.

      SC 13G - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      11/14/24 9:38:25 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

      SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

      11/13/24 10:27:59 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Arrowhead Pharmaceuticals Inc.

      SC 13G/A - ARROWHEAD PHARMACEUTICALS, INC. (0000879407) (Subject)

      10/16/24 9:15:20 AM ET
      $ARWR
      Biotechnology: Pharmaceutical Preparations
      Health Care